Glycemic Gap May Predict ST-Segment elevation MI Associated AKI after PCI in STEMI Patients: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-05-18 16:15 GMT   |   Update On 2025-05-18 16:16 GMT

China: Researchers have discovered that the glycemic gap (GG) serves as an independent risk factor for acute kidney injury related to ST-segment elevation myocardial infarction (STAAKI) following percutaneous coronary intervention (PCI) in STEMI patients. The study published in BMC Nephrology further demonstrated that including GG in existing risk prediction models markedly improves the ability to forecast STAAKI.

Advertisement

The investigation, conducted by Xiaofu Zhang and colleagues from the Department of Cardiology at The First People’s Hospital of Yuhang District in Hangzhou, China, and colleagues retrospectively analyzed data from 595 patients diagnosed with STEMI who underwent primary PCI. STAAKI, a serious complication that can significantly worsen patient outcomes, was observed in 9.2% of the study population.

The research team employed logistic regression to identify factors linked to the development of STAAKI.

The study revealed the following findings:

  • Left ventricular ejection fraction (LVEF), N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels and glycemic gap (GG) were significant independent predictors of ST-segment elevation myocardial infarction-associated acute kidney injury (STAAKI).
  • Each 1 mmol/L increase in the glycemic gap was linked to a 37.9% higher risk of developing STAAKI.
  • Every 1% increase in LVEF was associated with a reduced risk of STAAKI.
  • Higher levels of NT-proBNP correlated with an increased risk of STAAKI.
  • Restricted cubic spline analysis demonstrated a linear dose-response relationship between the glycemic gap and STAAKI risk, indicating that the risk rises proportionally as GG increases.
  • Incorporating the glycemic gap into existing risk prediction models significantly improved their accuracy, as confirmed by the Delong test, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) statistics.
  • This improved risk modeling may help clinicians better identify STEMI patients at risk for acute kidney injury after PCI and optimize treatment strategies.

However, the authors noted several limitations in their study. Being retrospective, the research cannot definitively establish a causal link between elevated glycemic gap and STAAKI. Additionally, the findings are based solely on STEMI patients, so further research is needed to confirm whether GG plays a similar predictive role in other conditions. The biological mechanisms underlying how an increased glycemic gap contributes to kidney injury remain unclear, highlighting the need for additional basic science investigations.

"The study emphasizes the prognostic importance of glycemic gap in STEMI patients undergoing PCI. It suggests that measuring and incorporating GG into clinical risk assessment could improve early identification of patients at heightened risk for acute kidney injury, potentially guiding more personalized treatment strategies," the researchers wrote.

"Future prospective studies are warranted to explore the mechanisms involved and to validate these findings in broader patient populations," they concluded.

Reference:

Zhang, X., Li, Y., Yang, Q. et al. Prognostic value of glycemic gap in ST-segment elevation myocardial infarction-associated acute kidney injury. BMC Nephrol 26, 243 (2025). https://doi.org/10.1186/s12882-025-04167-3


Tags:    
Article Source : BMC Nephrology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News